Paracetamol Hasco

Acetaminophen

Advertisements

Method of action: Analgesic, Anti-Inflammatory, Antipyretic, Pain Reliever

Treatment option: Arthralgia, Period Pain, Backache, Pain, Sore Throat, Earache, Headache, Influenza, Toothache, Fever

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Paracetamol Hasco

What is Paracetamol Hasco? Identity and Drug Classification

Property	Description
Active Ingredient	Paracetamol (Acetaminophen)
Forms	Tablet, Syrup, Oral Solution, Suppository
Pharmacological Class	Analgesic and Antipyretic
Common Use	Symptomatic relief of pain and fever
Origin	Synthetic organic compound

Paracetamol Hasco is a medicinal product whose active substance is Paracetamol, internationally recognized as Acetaminophen. This compound is a synthetic organic compound of the anilide chemical class and is supplied as a single-ingredient product. The substance is formally categorized as an analgesic (pain reliever) and an antipyretic (fever reducer).

Paracetamol is considered a non-opioid analgesic and is pharmacologically distinct from the classic Non-Steroidal Anti-inflammatory Drugs (NSAIDs), such as Ibuprofen. This is a differentiating factor, as Paracetamol's action is primarily centralized within the nervous system, and it exhibits minimal, if any, clinically relevant anti-inflammatory effects in the body at therapeutic doses. The product is commonly available over-the-counter (OTC), reflecting its established safety profile for broad patient access.

Forms, Origin, and General Therapeutic Purpose

Paracetamol Hasco is made available in several high-level dosage forms designed for either oral or rectal administration, ensuring widespread applicability across patient groups. These presentations typically include solid oral preparations like tablets, as well as liquid forms such as syrup or oral solution—often specialized to facilitate administration to children—and non-oral forms like suppositories.

The general therapeutic purpose of Paracetamol Hasco is the symptomatic relief of discomfort. It is primarily used to diminish the sensation of pain and to assist in normalizing elevated body temperature (fever), which are its two core therapeutic outcomes. The existence of multiple specialized forms helps ensure its suitability for a broad range of patients, accommodating different needs for ease of use.

Advertisements

What side effects are possible with Paracetamol Hasco?

Possible Side Effects and Safety Information

The safety profile of Paracetamol Hasco, whose active ingredient is Paracetamol (Acetaminophen), is primarily defined by the risks documented in official government regulatory labels concerning dose-related liver injury, hypersensitivity, and specific blood disorders.

Adverse Reaction Scope and Classification

Adverse reactions are formally grouped by the body system affected (System-Organ-Class or SOC). Most common effects at therapeutic doses are typically mild or classified by regulators as Rare or Very Rare.

System-Organ Classes Involved: The main focus is on Hepatobiliary Disorders (liver), Skin and Subcutaneous Tissue Disorders, Immune System Disorders, and Blood and Lymphatic System Disorders.
Rare Adverse Reactions: Side effects on the blood and lymphatic system, such as thrombocytopenia (low platelet count), and certain allergic reactions are generally classified as Rare.
Serious Adverse Reactions: The most critical safety concern is Severe Hepatotoxicity and Hepatic Failure, which is strongly linked to ingestion exceeding label limits (acute overdose). Other Very Rare but serious reactions documented include Anaphylactic Shock and Serious Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Dose, Duration, and Population Constraints

Official regulatory documents define specific limitations on use related to underlying health status and exposure patterns.

Dose-Related Risk: Regulatory warnings stress that the risk of severe liver damage is acute and dose-dependent. Chronic high-dose use is associated with the potential for blood dyscrasias and renal toxicity.
Safety Constraints: The medicine is strictly contraindicated in cases of known severe hypersensitivity to the active substance or severe, active liver disease. Caution is specified for individuals with impaired hepatic function, impaired renal function, and chronic, heavy alcohol consumption, as these factors may increase the risk of toxicity.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Paracetamol Hasco

This section defines the officially documented overdose profile for Paracetamol (Acetaminophen) as established by government regulatory sources.

Domain	Official Regulatory Documentation
Documented overdose presentations	Initial manifestations may include pallor, nausea, vomiting, and abdominal pain. Symptoms may be mild or absent in the first 24 hours, but do not reliably indicate the severity of toxicity. Delayed signs include jaundice (yellowing of skin/eyes) and loin pain (suggesting kidney effects).
Physiological systems affected	The primary concern is Hepatic (severe liver damage, hepatic necrosis, and potentially fatal liver failure). Other systems affected include Renal (acute renal failure) and Systemic (metabolic acidosis).
Population-specific overdose notes	An increased hazard of severe toxicity exists in patients with severe hepatic impairment, chronic alcoholism, malnutrition, or states of glutathione deficiency as explicitly defined in official labeling.
Emergency-response statements	Seek immediate medical advice or attention for any suspected overdose, regardless of whether symptoms are present. Urgent referral to a hospital is mandated due to the risk of severe, delayed, life-threatening hepatotoxicity.

Resulting Overdose Structure

Official overdose statements:

Mandatory Action: Regulatory documents require seeking immediate medical attention for suspected overdose because severe damage can occur without early symptoms.
Antidote: The specific antidote, N-acetylcysteine (NAC), is documented as essential for treatment to prevent or lessen hepatic injury.
Monitoring: Management requires hospital monitoring, including obtaining plasma paracetamol concentration at 4 hours or later post-ingestion to guide therapy using the official nomogram.

Connection to the overall overdose profile:

Regulatory documents define the overdose profile by focusing on the time-critical, delayed hazard of severe, life-threatening hepatic failure. This risk necessitates that the required help-seeking condition is one of immediate medical emergency, mandating urgent hospital assessment and the administration of the documented antidote, N-acetylcysteine.

Therapeutic Uses of Paracetamol Hasco

Paracetamol Hasco, whose active ingredient is Paracetamol (Acetaminophen), is relevant across therapeutic domains where short-term symptomatic assistance is needed for pain and fever. This active substance is widely used in over-the-counter and prescription medicines to temporarily relieve pain and reduce fever.

The medication is commonly used to help manage symptoms related to physical discomfort of mild-to-moderate intensity, which includes common, acute manifestations such as headache, muscle aches, backache, toothache, and period pain. It is also applied across domains where additional symptomatic support is needed for elevated body temperature (fever) and generalized body aches associated with cold and flu-like conditions. Its use contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability during symptomatic periods.

“Paracetamol Hasco is used to provide support that helps ease the overall symptom burden associated with acute, temporary discomfort.”

It is relevant when supportive symptom management is appropriate for various patient groups, including both adults and pediatric populations, and is considered relevant when supportive symptom management is appropriate for patients who require an alternative to Non-Steroidal Anti-inflammatory Drugs (NSAIDs).

Quick Fact: Relief for Acute Discomfort The core therapeutic focus is on the symptomatic relief of pain and the moderation of fever, supporting patients during episodes of heightened discomfort.

Regulatory References

NIH MedlinePlus overview of Pain Relievers

Advertisements

Eligibility and Restrictions for Use

Populations Who Must Not Use (Contraindicated)

Use of this medicine is absolutely contraindicated for patients with a documented history of hypersensitivity to Paracetamol (Acetaminophen) or any excipient in the formulation. It is also prohibited for patients diagnosed with severe hepatic impairment or severe active liver disease.

Populations Requiring Conditional or Restricted Use

Regulatory guidelines stipulate that use is restricted or requires caution for several groups. This includes patients with mild to moderate hepatic impairment (such as Gilbert's syndrome) and those with severe renal impairment, who may require adjustments to the dosing interval. Additionally, patients with conditions like chronic alcoholism, severe malnutrition, G6PD deficiency, or severe dehydration should use the medicine under caution.

Age and Special Eligibility Status

The medicine is approved for adults and adolescents. Pediatric use is established but strictly governed by minimum age thresholds, with certain forms not recommended for young children. For pregnant individuals, use is acceptable when clinically necessary, provided it is at the lowest effective dose and for the shortest duration. The medicine is generally considered compatible for use during breastfeeding.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions with Paracetamol (Acetaminophen) that are formally documented in government regulatory sources, detailing co-administration restrictions and kinetic modifications.

Classification	Interacting Substances/Conditions	Regulatory Statement Summary
Formal Contraindication	Other Paracetamol-containing products	Co-administration is explicitly prohibited due to a severe risk of liver damage and toxicity from accidental overdose.
Pharmacodynamic Effects	Warfarin and other Coumarins	Prolonged, regular daily use of Paracetamol can enhance the anticoagulant effect and increase bleeding risk; this necessitates increased International Normalized Ratio (INR) monitoring.
Metabolic/Toxicity Risk	Liver Enzyme Inducers (e.g., Phenytoin, Rifampicin, Barbiturates)	These agents may increase the formation of Paracetamol's toxic metabolite, heightening the risk of hepatotoxicity.
Exposure Modification	Metoclopramide or Domperidone	Officially documented to increase the rate of Paracetamol absorption and accelerate the onset of effect.
Clearance Reduction	Probenecid	Reduces Paracetamol clearance by preventing conjugation, requiring consideration for a dose reduction.
Absorption Restriction	Cholestyramine	Reduces Paracetamol absorption; must be administered at least 1 hour apart from Paracetamol, as per label instruction.

Population-Specific and Non-Medicine Cautions

The risk of hepatotoxicity is officially greater in individuals with chronic alcohol consumption or non-cirrhotic alcoholic liver disease. Additionally, the label notes that concomitant use with Flucloxacillin carries an increased risk of high anion gap metabolic acidosis, particularly in patients with pre-existing risk factors such as severe renal impairment or malnutrition.

Advertisements

Mechanism of Action

The action of Paracetamol (Acetaminophen) is achieved through a dual mechanism predominantly centralized within the Central Nervous System (CNS).

Modulating the Hypothalamic Thermoregulatory Center

This domain involves the reversible inhibition of Cyclooxygenase (COX) enzymes specifically within the hypothalamus. This action blocks the local synthesis of Prostaglandin E2 (PGE2), a key mediator that elevates the brain's internal temperature set point. The resulting physiological effect is the resetting of this set point, which allows the body to initiate mechanisms like sweating to lower the thermal output and restore baseline thermal regulation.

Central Inhibition of Nociceptive Pathways

The molecular impact on nociceptive signaling is multi-layered, beginning with central COX inhibition and extending to the action of its metabolite, AM404. AM404 activates the TRPV1 receptor and modulates the endocannabinoid and serotonergic systems, which are part of the endogenous inhibitory control of nociception. These actions collectively enhance the descending inhibitory pathways, resulting in an elevated threshold for nociceptive signaling within the CNS.

Mechanistic Constraints: The Role of Peroxidase

The mechanism is constrained by high levels of peroxidases found at peripheral inflammatory sites. These enzymes chemically inactivate Paracetamol, preventing effective inhibition of peripheral COX. This functional constraint explains the minimal inhibition of peripheral COX and the subsequent absence of effect on platelet aggregation or generalized peripheral anti-inflammatory pathways.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Administration of Paracetamol (Acetaminophen) must strictly follow the dosing and scheduling instructions provided in the official product labeling and accompanying patient information.

Approved Administration Routes

Paracetamol is approved for several administration routes, including Oral use (tablets, solution, suspension), Rectal use (suppository), and Intravenous use (infusion, administered by a healthcare professional).

Labeled Dosing and Regimens

Dosing is based on the patient's age and weight. The key constraint is the Maximum Total Daily Dose (MTDD), which must not be exceeded across all routes of administration within 24 hours.

Population	Single Dose Range	Minimum Dosing Interval	Maximum Total Daily Dose (MTDD)
Adults (>50 kg)	500 mg to 1000 mg (1 g)	4 hours	4000 mg (4 g)
Children	10 mg/kg to 15 mg/kg	4 to 6 hours	60 mg/kg (not to exceed 4 g)

Preparation and Scheduling Specifics

Frequency: Doses are typically spaced with a minimum interval of 4 hours between administrations. For patients with identified renal or hepatic impairment, the interval must be extended to 6 to 8 hours.

Preparation: Liquid formulations (suspensions) require shaking the bottle before the dose is measured using the provided dosing device to ensure accuracy. Certain oral powders must be fully dissolved in water, cooled, and consumed immediately.

Administration Conditions: The medicine can be taken with or without food. Self-treatment should not exceed 3 to 5 consecutive days without further consultation. If a dose is missed, it is instructed to take the next dose only after the minimum required interval has passed; a double dose must not be taken.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Paracetamol Hasco

Evidence for Symptomatic Relief of Acute Pain

Research involving Paracetamol was studied for acute physical discomfort through short-term randomized controlled trials (RCTs) and systematic reviews. These studies examined patient-reported experiences related to physical discomfort by measuring change in pain intensity and the need for rescue medication in contexts like headache and surgical recovery. Findings describe measured outcomes that varied depending on the condition. The certainty remains low for drawing conclusions across the wide range of general acute pain, and the data on outcomes related to a single dose are more common than data on multi-day use.

Evidence for Symptomatic Reduction of Elevated Body Temperature (Fever)

The active ingredient was studied for research exploring outcomes related to systemic imbalance, utilizing RCTs comparing it against placebo or other agents. Studies explored outcomes by measuring the absolute change in core body temperature and the time taken for the temperature to decrease, mostly in pediatric populations. Comparative research explored differences when the ingredient was compared to NSAIDs. Limited high-quality research was observed in adult populations, and long-term effects on the overall course of illness are not fully established.

Evidence in Select Chronic Pain Conditions

The ingredient was studied for use in conditions characterized by functional limitations, with research exploring conditions such as knee or hip osteoarthritis (OA). Studies monitored changes in pain intensity scores, and findings indicate patterns related to changes in measurements in certain OA locations. However, research describes that data show patterns related to a lack of observed effect when the ingredient was evaluated in studies of acute low back pain. The evidence quality varies across studies, and certainty remains low for chronic pain outside specific, well-studied OA populations.

Long-term Follow-up and Duration of Effect

Studies monitoring responses over defined time intervals beyond several weeks are comparatively fewer. Comprehensive data describing the long-term patterns of use over months or years is not fully established, meaning the durability of the symptom-relief effect remains uncertain across many indications.

Evidence in Special Populations

The ingredient was evaluated in specific groups, including children and older adults. Systematic reviews conducted to identify high-quality RCTs for chronic non-cancer pain in children and adolescents did not find any eligible studies. This limitation indicates that the data for chronic pain in these groups remain insufficient.

What Research Gaps and Uncertainties Remain

Several key research limitation frames persist, including limited follow-up durations in acute studies and limited comparative evidence against other agents. The evidence quality varies across studies, and research highlights what is known—and what is still uncertain.

Key Studies & References

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Paracetamol Hasco (FAQ)

Q: Does Paracetamol Hasco contain any ingredients besides paracetamol?

Yes, Paracetamol Hasco formulations contain ingredients other than the active substance (paracetamol). These are referred to as inactive ingredients or excipients. A complete list of these substances is detailed in the official regulatory documents, such as the Summary of Product Characteristics (SmPC) or the Patient Information Leaflet (PIL) for the specific product form you are using.

Q: How quickly can I expect Paracetamol Hasco to start working?

According to official pharmacokinetic information, the active substance is readily absorbed into the body after it is administered orally. Peak concentrations, which indicate the highest amount in the bloodstream, are generally observed between 10 to 60 minutes after the product is taken.

Q: How long do the effects of Paracetamol Hasco usually last?

The duration of the substance's presence in the body is described by its pharmacokinetic properties. Official documents indicate that the time it takes for half of the substance to be eliminated, known as the elimination half-life, is typically between 1 to 3 hours in healthy adults.

Q: Is Paracetamol Hasco generally considered appropriate for older adults?

Official information generally establishes suitability for adults. Regulatory documents state that for older adults, particularly those who are frail, official guidance may stipulate extended intervals between administrations or dosage adjustments, which reflects how the body’s processing of the substance may change with age.

Q: Is it possible for Paracetamol Hasco to cause stomach upset?

Official regulatory documents list side effects related to the digestive system (gastrointestinal adverse reactions). These reports include effects such as nausea and vomiting, which are noted in regulatory safety documents as possible adverse reactions associated with the active substance.

Q: Is Paracetamol Hasco available in different strengths?

Yes, official product information confirms that products containing the active substance are commonly available in different strengths and forms. These various presentations, such as 500 mg tablets or specific milligram-per-milliliter liquid suspensions, are designed to suit different patient groups and administration needs.

Q: What official documents describe the half-life of paracetamol in the body?

The half-life of the active substance is described in the pharmacokinetics section of official drug documents. This section, typically listed as 5.2 in the Summary of Product Characteristics (SmPC), contains factual data on the pharmacokinetic properties of the substance.

Q: Is Paracetamol Hasco indicated for nerve pain?

The product is indicated for the symptomatic relief of various types of discomfort. This includes general aches and pains and, in some official documents, explicitly mentions the symptomatic relief of 'nerve pains' among its uses.

Q: Are the inactive ingredients of Paracetamol Hasco known to cause any side effects?

Official warnings state that a known allergy or hypersensitivity to any of the inactive ingredients (excipients) constitutes a contraindication for the use of the medicine. Furthermore, certain excipients, such as specific preservatives, may carry additional warnings for rare allergic reactions or risks in specific populations, such as newborns.

Q: Is it acceptable to crush or chew Paracetamol Hasco tablets?

Official instructions for administration typically state that tablets should be swallowed whole. Some documents describe that a break line is provided only to make the tablet easier to swallow. Official documents describe that the method of administration for tablets is swallowing them whole, and modifying the tablet form is not typically described as an approved method of administration unless the product is specifically labeled otherwise.

Q: Is it normal to feel drowsy after taking Paracetamol Hasco?

Official product information occasionally includes reports of neurological effects like light-headedness or dizziness. However, the medicine is generally stated in regulatory documents to have no significant impact on a person's ability to operate machinery or drive a vehicle.

Q: What information is provided regarding interactions with specific herbal supplements?

Formal product information typically focuses on interactions with other medicinal products. However, government health monitoring bodies generally note that the active substance is not widely affected by common herbal remedies. Official guidance stresses that informing a healthcare practitioner of all concomitant supplements is an important safety measure.

Q: Is there a classification or warning about operating machinery while using Paracetamol Hasco?

Official product information, often in a section titled 'Effects on ability to drive and use machines,' states that the active substance in Paracetamol Hasco is considered to have no influence or a negligible influence on the user's ability to drive or operate machinery.

Q: Does Paracetamol Hasco interact with vaccines?

Regulatory guidelines and immunization handbooks address this topic. They state that the active substance may be used to manage fever or pain that occurs after a vaccination. Guidance from regulatory and immunization bodies describes the use of the substance preventatively as generally not indicated, though specific exceptions may exist, such as for very young infants.

Q: What is the potential impact of Paracetamol Hasco on laboratory tests?

Official product information notes that the active substance can interfere with the accuracy of certain laboratory test results. Specifically, paracetamol at common therapeutic amounts may affect tests that measure the levels of uric acid and glucose in the blood.

Q: What common household products might contain paracetamol that a user should be aware of?

Government health and consumer safety authorities warn that the active substance is a frequent component of many combined or multi-symptom drug products. These most often include various cold, flu, and allergy remedies. Checking the active ingredient name on all medicine labels is described as a critical step to mitigate the risk of accidental co-administration and overdose.

Q: How is the suitability of Paracetamol Hasco determined for individuals with a history of asthma?

The suitability is related to the substance’s action, which is primarily centralized and associated with minimal effects on certain peripheral enzymes. Official information describes that individuals with a history of asthma are generally recommended to discuss the use of all medications with a healthcare practitioner.

Advertisements

How should Paracetamol Hasco be stored and disposed of?

How to Store and Dispose of Paracetamol Hasco?

The official labeling mandates strict conditions for the storage and disposal of Paracetamol Hasco to maintain product integrity and safety.

Storage Requirements

Storage Condition	Requirement
Temperature	Store below 25 C and do not freeze.
Protection	Store in the original packaging to protect from light.
Child Safety	Keep out of the sight and reach of children.

The oral suspension must be kept tightly closed. The stability after first opening is typically 3 months for the standard suspension and 12 months for the Forte suspension.